NEW YORK (GenomeWeb News) – Nanosys and Harvard University have licensed certain patents and patent applications to Vista Therapeutics covering the use of nanowires for biosensors.
Under terms of the license, Louisville, Ky.-based Vista has received exclusive, worldwide rights to use nanowires for detection of biomarkers associated with organ or tissue damage, as well as any form of treatment-associated adverse response. In return, Harvard and Nanosys have received an undisclosed equity stake in Vista, upfront license fees, and will receive downstream royalty payments.
The core intellectual property was developed by Charles Lieber, a professor of chemistry at Harvard, and covers a range of applications in nanotechnology, nanomaterials, and the use of nanowire-based field effect transistors as biosensors. According to the partners, Lieber's inventions enable continuous and real-time monitoring of multiple biomarkers in blood and urine.
"Just as EKG instruments allow physicians to continuously monitor a patient's heart function, the broad nanowire IP portfolio acquired in these agreements will allow Vista to commercialize and market its NanoBioSensor platform that enables physicians, clinicians and pharmaceutical researchers to continuously monitor, on a real-time basis, a wide variety of blood and urinary biomarkers," Spencer Farr, founder and CEO of Vista, said in a statement.